1. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update;Canadian journal of diabetes,2016
2. Review of diabetes medicines called SGLT2 inhibitors started;Risk of diabetic ketoacidosis to be examined: European Medicines Agency,2015
3. Forxiga, Invokana: Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosis. In: Canada H, ed. Ottawa, ON, Canada: Health Canada; 2015.
4. U.S. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood: U.S. Food and Drug Administration; 2015.
5. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 inhibitors and diabetic ketoacidosis;Handelsman;Endocr Pract,2016